Report from Bluefish Pharmaceuticals AB’s Extraordinary Shareholders’ Meeting
On November 22, 2007, Bluefish Pharmaceuticals AB held an extraordinary shareholders’ meeting at 14.00 pm in Stockholm.
Election of members of the board of directors
The shareholders´ meeting resolved that the Board will consist of four ordinary and no deputy board members. The shareholders´ meeting resolved to elect Erika Kjellberg Eriksson and Carl Palmstierna as new ordinary members of Bluefish Pharmaceuticals. Bo Rönnberg has chosen to resign as an ordinary member of the board of directors and Björn Magnusson has chosen to resign as a deputy member of the board of directors of Bluefish Pharmaceuticals. The board of directors will consist of Karl Karlsson, Erika Kjellberg Eriksson, Carl Palmstierna and Lars-Göran Kjellin.
For more information, please contact: Karl Karlsson, President & CEO, tel +46 8-679 50 70
Bluefish Pharmaceuticals AB is a Swedish pharmaceutical company that licenses, develops,manufactures and markets mainly generic pharmaceutical products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly‐owned subsidiary in Chennai,India, focusing on product development and production. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.